Merck & Co. saw its shares rise on Thursday by over 5% as the company’s closely watched Covid-19 antiviral molnupiravir could bring in as much as $7 billion in global sales through 2022, according to the drugmaker. This figure includes up to $1 billion revenue in 2021 if the drug is authorized in December said … Continue reading “Merck Shares Rise as Covid Antiviral Sales Could Mean Billions for the Company”
